Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients

British Journal of Cancer

Volumn 112, Issue 6, 2015, Pages 1114-1120

  Zajkowicz, A ^a   Butkiewicz, D ^a   Drosik, A ^a   Giglok, M ^a   Suwinski R ^a   Rusin, M ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

lung cancer; mosaicism; p53 phosphorylation; PPM1D; truncating mutations

Indexed keywords

DNA; PROTEIN BAX; PROTEIN MDM2; PROTEIN P53; RECOMBINANT DNA; SERINE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN PHOSPHATASE 2C; STOP CODON; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD CELL; BLOOD SAMPLING; CANCER PATIENT; CONTROLLED STUDY; FEMALE; FRAMESHIFT MUTATION; GENE; GERMLINE MUTATION; HUMAN; IMMUNOBLOTTING; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PPM1D GENE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; BLOOD; DNA DAMAGE; EXON; GENETICS; LUNG TUMOR; PROMOTER REGION; STOP CODON; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CODON, NONSENSE; DNA DAMAGE; DNA, NEOPLASM; EXONS; FEMALE; FRAMESHIFT MUTATION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPROTEIN PHOSPHATASES; PROMOTER REGIONS, GENETIC; SERINE; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84925303588     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.79     Document Type: Article

References (20)

1. Akbari MR, Lepage P, Rosen B, McLaughlin J, Risch H, Minden M, Narod SA (2014) PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. J Natl Cancer 106: djt323.
2. Allan JM, Travis LB (2005) Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 5: 943-955.
3. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915.
4. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674-1677.
5. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677-1679.
6. Fuchs B, OConnor D, Fallis L, Scheidtmann KH, Lu X (1995) p53 phosphorylation mutants retain transcription activity. Oncogene 10: 789-793.
7. Jaks V, Jõers A, Kristjuhan A, Maimets T (2001) p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle agrest after treatment of cells with camptothecin. Oncogene 20: 1212-1219.
8. Kleiblova P, Shaltiel IA, Benada J, ͈evɥi J, PechâkovaS, Pohlreich P, Voest EE, Dundr P, Bartek J, Kleibl Z, Medema RH, Macurek L (2013) Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. J Cell Biol 201: 511-521.
9. Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137: 609-622.
10. Lu X, Bocangel D, Nannenga B, Yamaguchi H, Appella E, Donehower LA (2004) The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Mol Cell 15: 621-634.
11. Lu X, Nannenga B, Donehower LA (2005) PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 19: 1162-1174.
12. McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, Thomas DM, Mitchell G (2014) Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol 11: 260-271.
13. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299.
14. Oliva-Trastoy M, Berthonaud V, Chevalier A, Ducrot C, Marsolier-Kergoat MC, Mann C, Leteurtre F (2007) The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase. Oncogene 26: 1449-1458.
15. Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, Rodrigues DN, Renwick A, Seal S, Ramsay E, Duarte Sdel V, Rivas MA, Warren-Perry M, Zachariou A, Campion-Flora A, Hanks S, Murray A, Ansari Pour N, Douglas J, Gregory L, Rimmer A, Walker NM, Yang TP, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Eccles D, Evans DG, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L, Gore M, Houlston R, Brown MA, Caufield MJ, Deloukas P, McCarthy MI, Todd JA. Breast and Ovarian Cancer Susceptibility Collaboration; Wellcome Trust Case Control ConsortiumTurnbull C, Reis-Filho JS, Ashworth A, Antoniou AC, Lord CJ, Donnelly P, Rahman N (2013) Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 493: 406-410.
16. Shiloh Y (2003) ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3: 155-168.
17. Shreeram S, Demidov ON, Hee WK, Yamaguchi H, Onishi N, Kek C, Timofeev ON, Dudgeon C, Fornace AJ, Anderson CW, Minami Y, Appella E, Bulavin DV (2006) Wip1 phosphatase modulates ATMdependent signaling pathways. Mol Cell 23: 757-764.
18. Zajkowicz A, Krzesiak M, Matuszczyk I, Gowala-Kosinka M, Butkiewicz D, Rusin M (2013) Nutlin-3a, an MDM2 antagonist and p53 activator, helps to preserve the replicative potential of cancer cells treated with a genotoxic dose of resveratrol. Mol Biol Rep 40: 5013-5026.
19. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M (1995) A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 23: 2584-2592.
20. Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, Yang S, Jones S, Wang S, Zhou W, Zhu H, Killela PJ, Zhang J, Wu Z, Li G, Hao S, Wang Y, Webb JB, Friedman HS, Friedman AH, McLendon RE, He Y, Reitman ZJ, Bigner DD, Yan H (2014) Exome sequencing identifies somatic gain-offunction PPM1D mutations in brainstem gliomas. Nat Genet 46: 726-730.